BTX vs. CIDM, ALFIW, and NLOK
Should you be buying Brooklyn ImmunoTherapeutics stock or one of its competitors? The main competitors of Brooklyn ImmunoTherapeutics include Cinedigm (CIDM), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.
Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.
8.0% of Cinedigm shares are owned by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 16.4% of Cinedigm shares are owned by insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.
In the previous week, Cinedigm and Cinedigm both had 1 articles in the media. Brooklyn ImmunoTherapeutics' average media sentiment score of 0.00 equaled Cinedigm'saverage media sentiment score.
Cinedigm has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, meaning that its share price is 361% more volatile than the S&P 500.
Summary
Brooklyn ImmunoTherapeutics beats Cinedigm on 4 of the 6 factors compared between the two stocks.
Get Brooklyn ImmunoTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brooklyn ImmunoTherapeutics Competitors List
Related Companies and Tools
